{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-093520","form_type":"8-K","ticker":"APTN","cik":"0001938571","company_name":"ADAPTIN BIO, INC.","filed_at":"2026-08-25T20:10:32+00:00","discovered_at":"2026-08-25T20:11:06.833367+00:00","generated_at":"2026-08-25T20:11:27.651692+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Adaptin Bio opens enrollment in Phase 1 trial of APTN-101 for glioblastoma","bullets":["Enrollment opened in Phase 1 open-label dose-escalation trial of APTN-101 (BRiTE T-cell engager) for EGFRvIII-positive GBM, at Duke University, up to 15 adult patients.","Primary endpoint is proportion of patients with dose-limiting toxicity per dose level; secondary endpoints include pharmacokinetics and objective response rate (modified RANO).","Preclinical data: APTN-101 showed >7-fold increase in brain distribution vs EGFRvIII engager alone and complete tumor eradication in 70-80% of mice models.","GBM is ~15,000 new U.S. cases/year; market valued at $3.02B (2025), projected $4.44B by 2030 (8% CAGR)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-093520","json":"https://secwatch.observer/filing/0001213900-26-093520.json","markdown":"https://secwatch.observer/filing/0001213900-26-093520.md","text":"https://secwatch.observer/filing/0001213900-26-093520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938571/000121390026093520/0001213900-26-093520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938571/000121390026093520/ea0303128-8k_adaptin.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T20:11:27.651692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}